Good morning, Your MarketBeat account is almost ready! You’ve successfully created your account, but it’s not fully active yet because your email address (reed791.worldnews@blogger.com) still needs to be verified. We require that all new users verify their email address so that we can keep your daily newsletter out of the spam folder.
Fortunately, verifying your email address is simple. It only takes one click.
Verify Your Email Address
Talk soon,
Laycee Kluin
Digital Marketing Team, MarketBeat
Special Report Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Authored by Nathan Reiff. Originally Published: 2/2/2026. 
In Brief - Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results.
- Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity.
- USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals.
Nearly a month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall despite multiple dips throughout January. That middling performance, however, masks the fact that several individual companies have delivered supercharged starts to the year, dramatically outperforming the market benchmark. Investors looking to capitalize on rising momentum in 2026 may want to consider Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR), all of which have returned at least 56% year-to-date (YTD). Analysts Stay Bullish on Corvus, See 50%+ Upside On September 14th, 2023, something big happened that didn't make the news. The price gap between London gold and Shanghai gold blew out to $120 an ounce. For years, that gap was a few dollars, maybe $5 or $10. A 20x jump in seconds isn't a glitch, it's the system breaking. Traders tried to buy gold in London to sell in Shanghai, but hit a wall. The London vaults were empty. Since that day, gold has hit 53 all-time highs. One stock is positioned to capture the bulk of this wealth transfer. See the full story on this opportunity now. As a clinical-stage biopharma company, Corvus operates in a sector known for rapid and sizable stock swings in either direction. One recent catalyst for Corvus's share movement was positive data for soquelitinib, its drug candidate for atopic dermatitis and other conditions. In mid-January, Corvus reported promising Phase 1 results, including a 72% reduction in eczema severity among trial patients. That news helped Corvus shares surge roughly 188% YTD. A Phase 2 trial is planned for early 2026 and could push shares higher. To bankroll the upcoming trial, Corvus initiated a $150 million equity offering, which should provide a much-needed cash runway but could dilute existing shareholders. That funding is important because Corvus ended the third quarter of 2025 with only $67 million in cash. While the company is banking on soquelitinib's continued success, the addressable market for atopic dermatitis patients is sizable. Analysts are generally bullish: six of seven rate CRVS a Buy, and the consensus price target implies roughly 51% upside even after the recent rally. New Era's Data-Center Pivot Makes Strides, Though Legal and Other Risks Remain New Era & Digital is among the more polarizing names for investors focused on energy exploration and production in 2026. NUAI shares are up more than 114% YTD after the company announced in January a key partnership with Primary Digital Infrastructure to co-develop up to 1 gigawatt of hyperscale data-center capacity in Texas. The deal is an important step in New Era's pivot toward the high-demand data-center market. Earlier in the month, the company also closed the acquisition of a 50% ownership interest in Texas Critical Data Centers, further positioning it for the new focus. These moves suggest New Era could succeed in its ambitious reorganization. However, the company faces legal scrutiny: the Rosen Law Firm has announced plans to investigate allegations of "materially misleading business information." New Era's market value is under $400 million, which makes it a high-risk investment. Investors willing to accept those risks may be rewarded if the rally continues, but the position remains speculative. USA Rare Earth Looks to Fill a Significant Supply-Chain Need With Government Support Rare-earth minerals are increasingly critical to many technologies, and supply-chain and trade concerns threaten U.S. access. USA Rare Earth aims to provide a domestic alternative. The company has been buoyed by a $1.6-billion investment from the federal government and additional private investments in recent weeks, on top of a strong cash position reported with its latest earnings. The firm's rare-earth and magnet production capacity is expanding rapidly thanks to key operations in Texas, and revenues are expected to rise substantially. Still, USA Rare Earth remains an early-stage company without a proven track record of profitability, which may deter some investors. That said, its 56% YTD return and a strongly optimistic analyst rating profile suggest meaningful upside if the company executes on its plans.
| 
No comments:
Post a Comment